Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-29 | GeneDx Holdings Corp. | Feeley Kevin
(CHIEF FINANCIAL OFFICER) |
S | Class A Common Stock | D | 1104 | $11.04 - $11.04 | $12,184 |
| 2024-04-29 | GeneDx Holdings Corp. | Feeley Kevin
(CHIEF FINANCIAL OFFICER) |
M | Class A Common Stock | A | 3013 | $0.00 - $0.00 | $0 |
| 2024-03-12 | GeneDx Holdings Corp. | Feeley Kevin
(CHIEF FINANCIAL OFFICER) |
S | Class A Common Stock | D | 931 | $9.21 - $9.21 | $8,574 |
| 2024-03-09 | GeneDx Holdings Corp. | Feeley Kevin
(CHIEF FINANCIAL OFFICER) |
M | Class A Common Stock | A | 2462 | $0.00 - $0.00 | $0 |
| 2024-03-09 | GeneDx Holdings Corp. | Stueland Katherine
(CHIEF EXECUTIVE OFFICER) |
M | Class A Common Stock | A | 6547 | $0.00 - $0.00 | $0 |
| 2024-03-09 | GeneDx Holdings Corp. | Saad Kareem
(CHIEF TRANSFORMATION OFFICER) |
M | Class A Common Stock | A | 2841 | $0.00 - $0.00 | $0 |
| 2024-03-04 | GeneDx Holdings Corp. | Casdin Partners F...
(Director) |
P | Class A Common Stock | A | 40900 | $8.74 - $8.83 | $357,651 |
| 2024-01-03 | GeneDx Holdings Corp. | Saad Kareem
(Chief Transformation Officer) |
S | Class A Common Stock | D | 105 | $2.58 - $2.58 | $270 |
| 2024-01-01 | GeneDx Holdings Corp. | Saad Kareem
(Chief Transformation Officer) |
M | Class A Common Stock | A | 273 | $0.00 - $0.00 | $0 |
| 2023-12-18 | GeneDx Holdings Corp. | Stueland Katherine
(Chief Executive Officer) |
S | Class A Common Stock | D | 11734 | $2.16 - $2.16 | $25,338 |
| 2023-12-16 | GeneDx Holdings Corp. | Stueland Katherine
(Chief Executive Officer) |
M | Class A Common Stock | A | 18750 | $0.00 - $0.00 | $0 |
| 2023-12-11 | GeneDx Holdings Corp. | Stueland Katherine
(Chief Executive Officer) |
S | Class A Common Stock | D | 3673 | $1.61 - $1.61 | $5,914 |
| 2023-12-09 | GeneDx Holdings Corp. | Stueland Katherine
(Chief Executive Officer) |
M | Class A Common Stock | A | 6546 | $0.00 - $0.00 | $0 |
| 2023-11-16 | GeneDx Holdings Corp. | Ryan Jason
(Executive Chairman) |
P | Class A Common Stock | A | 114742 | $1.27 - $1.54 | $161,367 |
| 2023-11-15 | GeneDx Holdings Corp. | Corvex Management LP
(AtLeastTenPercentOwner) |
S | Class A Common Stock | D | 883742 | $1.29 - $1.29 | $1,140,027 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |